West Pharmaceutical Services stock rises 1.18% and outperforms sector rivals

7 articles · Updated · MarketWatch · Apr 29

Shares closed at $295.36 on Wednesday, snapping a three-day losing streak despite the S&P 500 and Dow Jones both declining.
West Pharmaceutical Services outperformed competitors like Abbott Laboratories, Becton Dickinson, and Baxter International, all of which saw notable losses during the session.
The stock remains 8.37% below its 52-week high of $322.34, with trading volume below its 50-day average, reflecting resilience amid a broadly negative market.

Is Becton Dickinson's new FDA-approved device an overlooked catalyst for its declining stock?

Did a $21 billion acquisition create a major risk for Abbott Labs, or a new growth opportunity?

Is West Pharma's high valuation justified by its role in the booming GLP-1 drug market?

As pharma's biggest drugs face a $400B patent cliff, how will key suppliers be impacted?

How will West Pharma's new Dublin plant help it dominate the European drug components market?

How will AI and recurring revenue models reshape the MedTech industry's competitive landscape?